Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride, quantity: 3.36 mg (equivalent: granisetron, qty 3 mg) - injection, concentrated - excipient ingredients: water for injections; sodium chloride; nitrogen; citric acid monohydrate; sodium citrate dihydrate - granisetron injection is indicated in:,adults: - for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy - for the prevention of nausea and vomiting induced by radiotherapy,children: - for the prevention of nausea and vomiting induced by cytotoxic chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride, quantity: 1.12 mg (equivalent: granisetron, qty 1 mg) - injection, concentrated - excipient ingredients: water for injections; sodium chloride; nitrogen; sodium citrate dihydrate; citric acid monohydrate - granisetron injection is indicated in:,adults: - for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy - for the prevention of nausea and vomiting induced by radiotherapy,children: - for the prevention of nausea and vomiting induced by cytotoxic chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - granisetron hydrochloride, quantity: 1.12 mg (equivalent: granisetron, qty 1 mg) - injection - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide; sodium chloride; citric acid monohydrate - adults: granisetron injection is indicated for use in adults for:,the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy;,the prevention of nausea and vomiting induced by radiotherapy.,granisetron injection is also indicated for use in the prevention and treatment of post-operative nausea and vomiting.,children: granisetron injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - granisetron hydrochloride, quantity: 3.36 mg (equivalent: granisetron, qty 3 mg) - injection - excipient ingredients: citric acid monohydrate; hydrochloric acid; sodium hydroxide; sodium chloride; water for injections - adults: granisetron injection is indicated for use in adults for:,the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy;,the prevention of nausea and vomiting induced by radiotherapy.,granisetron injection is also indicated for use in the prevention and treatment of post-operative nausea and vomiting.,children: granisetron injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride injection is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (eg. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. pregnancy  category  b reproduction studies have been performed in pregnant rats at intravenous doses up to 9 mg/kg/day (54 mg/m2 /day, 146 times the recommended human dose based on body surface area) and pregnant rabbits at intravenous doses up to 3 mg/kg/day (35.4 mg/m2 /day, 96 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predi

United States - English - NLM (National Library of Medicine)

yung shin pharmaceutical inc. co., ltd. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride injection usp is a serotonin-3 (5-ht3) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high- dose cisplatin. - the prevention and treatment of postoperative nausea and vomiting in adults. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (eg. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. teratogenic effects pregnancy category b reproduction studies have been performed in pregnant rats at intravenous

United States - English - NLM (National Library of Medicine)

yung shin pharmaceutical inc. co., ltd. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride injection, usp is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high- dose cisplatin. - the prevention and treatment of postoperative nausea and vomiting in adults. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection, usp is recommended even where the incidence of postoperative nausea and/or vomiting is low. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (eg. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. teratogenic effects pregnancy category b reproduction studies have been performed in pregnant rats at intra

United States - English - NLM (National Library of Medicine)

wockhardt limited - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 0.1 mg in 1 ml - - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. it is not known whether granisetron is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when granisetron hydrochloride injection is administered to a nursing woman. chemotherapy-induced nausea and vomiting [see dosage and administration (2)]  for use in chemotherapy-induced nausea and vomiting in pediatric patients 2 to 16 years of age. safety and effectiveness in pediatric patients under 2 years of age have not been established.

United States - English - NLM (National Library of Medicine)

wockhardt limited - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg in 1 ml - - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. it is not known whether granisetron is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when granisetron hydrochloride injection is administered to a nursing woman. chemotherapy-induced nausea and vomiting [see dosage and administration (2)]  for use in chemotherapy-induced nausea and vomiting in pediatric patients 2 to 16 years of age. safety and effectiveness in pediatric patients under 2 years of age have not been established.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride injection, usp is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (eg. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. teratogenic effects pregnancy category b reproduction studies have been performed in pregnant rats at intravenous doses up to 9 mg/kg/day (54 mg/m2 /day, 146 times the recommended human dose based on body surface area) and pregnant rabbits at intravenous doses up to 3 mg/kg/day (35.4 mg/m2 /day, 96 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not